Immunotherapy for Hepatocellular Carcinoma and Its New Development
Received Date: Jan 18, 2019 / Accepted Date: Feb 11, 2019 / Published Date: Feb 18, 2019
Hepatocellular Carcinoma (HCC) is the most common primary liver cancer with high mortality. Because of the limitation on the conventional therapeutic options and immunological characters of this disease, variable immunotherapy strategies for HCC have been designed and investigated. A few of them look promising. In this review, we comprehensively summarized recent and novel immunotherapies for HCC, with a particular focus on clinical trials on the basis of their physiological rationales for these strategies. Insights into these clinical progress and their ideologies are essential to improve efficacy and clinical outcome of these immunotherapies
Keywords: Hepatocellular carcinoma; Immunotherapy; liver tolerance; Clinical trial
Citation: Li H, Gyory I, Zhang X, Xu M, Xiong S (2019) Immunotherapy for Hepatocellular Carcinoma and Its New Development. J Oncol Res Treat 4: 134.
Copyright: © 2019 Li H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Open Access Journals
- Total views: 1673
- [From(publication date): 0-0 - Apr 16, 2021]
- Breakdown by view type
- HTML page views: 1561
- PDF downloads: 112